Part One: The Question of MRD in CLL Therapy
The HemOnc Pulse
00:00
Exploring the Impact of MRD in CLL Therapy
This chapter delves into the significance of measurable residual disease (MRD) in chronic lymphocytic leukemia (CLL) treatment, discussing its potential influence on therapy duration, patient outcomes, and treatment selection. The speakers highlight ongoing trials investigating MRD-guided therapies, the challenges of implementing MRD-guided therapy in clinical practice, and the importance of achieving MRD negativity for patient benefit.
Transcript
Play full episode
